90 likes | 156 Views
Patient enrollment in SAGE. Prakash Deedwania, et al. Circulation 2007;115:700-707. Baseline Characteristics of Patients Randomized in the SAGE Study. Prakash Deedwania, et al. Circulation 2007;115:700-707.
E N D
Patient enrollment in SAGE Prakash Deedwania, et al. Circulation 2007;115:700-707
Baseline Characteristics of Patients Randomized in the SAGE Study Prakash Deedwania, et al. Circulation 2007;115:700-707
Mean total duration of myocardial ischemia over 48 hours at baseline, month 3, and month 12 in the modified intent-to-treat population Prakash Deedwania, et al. Circulation 2007;115:700-707
Least-squares mean percent changes in lipid parameters from baseline Prakash Deedwania, et al. Circulation 2007;115:700-707
Summary of Results for Primary Efficacy Parameters and Secondary Efficacy Parameters at Month 12 Prakash Deedwania, et al. Circulation 2007;115:700-707
Kaplan-Meier plot for the time to the first MACE end point up to month 12. *At risk at month 12 plus 8 days Prakash Deedwania, et al. Circulation 2007;115:700-707
Kaplan-Meier estimates of time to all-cause death during the 12-month treatment period. *At risk at month 12 plus 8 days Prakash Deedwania, et al. Circulation 2007;115:700-707
Summary of MACE During the SAGE Study Prakash Deedwania, et al. Circulation 2007;115:700-707
Summary of All-Cause Safety Results Prakash Deedwania, et al. Circulation 2007;115:700-707